300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Mobile
Oil and Gas
Film
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Sports
Education
Biotechnology
Legal
Automotive
eSports
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Beauty
Fashion
Web3
Infrastructure
Recruiting
Social
Celebrity
Food and Beverage
Cannabis
LGBT
Life Science
Climate
Real Estate
Sporting Goods
Publishing
Music
Art
Wine and Spirits
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Mobile Apps
Android
Impact
Proptech
Hardware
Enterprise
Transportation
Biotech
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Colombia
Cameroon
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Honduras
Israel
Lithuania
Cambodia
Iceland
Liechtenstein
Mongolia
Lebanon
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Fund Twenty8, VC Fund

Fund Twenty8

VC Fund

Cambridge, United Kingdom

Fund Twenty8 is a VC fund in Cambridge focused on Health Care and Medical. Smart Beta for Early stage investing - Fund Twenty8The fund is the first passive EIS fund for early stage investments. It will deliver a multi-sector and large portfolio for investors.They believe Fund Twenty8 addresses two key areas currently underserved by the EIS fund market. A lack of sector diversification within a fund and a failure tobenefit from a wide portfolio approach investing. Traditional early stage funds usually focus on a single sector (exposing investors to sector-specific risks) and usually only invest in 5 to 8 investments per fund. They feel there is a need in the market for a multi-sector and large portfolio fund for early stage investments. That's why they created Fund Twenty8.Fund Twenty8 offers investors access to a diversified portfolio with at least 28 investments per fund and across multiple sectors.

Total investments:
34
Last investment:
Lead investor:
3%
Fund size:
$5.9M
Last fund:

Last updated:

Industries Fund Twenty8 invests in

Health CareMedicalBiotechnologyMedical DeviceSoftware

Stages Fund Twenty8 invests in

SeedVenture - Series UnknownSeries ASeries BAngel

Countries Fund Twenty8 invests in

United KingdomUnited States

Round sizes

Seed $508k–$1.9MSeries A $2.3M–$3.4MVenture - Series Unknown $414k–$3.1M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Seed
$508k–$1.9M
Series A
$2.3M–$3.4M
Venture - Series Unknown
$414k–$3.1M

Investment Focus

Industry

  • Health Care 10 (29%)
  • Medical 8 (24%)
  • Biotechnology 5 (15%)
  • Medical Device 5 (15%)
  • Software 3 (9%)
See all 66 industries →

Stage

  • Seed 17 (50%)
  • Venture - Series Unknown 9 (26%)
  • Series A 2 (6%)
  • Series B 2 (6%)
  • Angel 1 (3%)
See all 7 stages →

Country

  • United Kingdom 32 (94%)
  • United States 1 (3%)

Team

NameTitleInvestmentsLinksEmail
CEO Total investments: 1
Find email

Investments

CompanyDescriptionRoundLinks
We are Liopa. We were incorporated in 2015 to commercialise more than 15 years of PhD research at QUB in the field of speech and image processing. Using this deep knowledge, we developed an automated lipreading solution. Our technology – rooted in machine learning and AI – can decipher what a person is saying from their lip movements alone.Liopais the first company to release commercially available VSR (Visual Speech Recognition) technology, with the first application being our SRAVI app (www.sravi.ai). SRAVI is a simple lipreading application that requires just a smartphone. It is bringing a voice to the voiceless. With SRAVI, we help patients who have lost the ability to speak, to communicate with their loved ones & carers. SRAVI is deployed onto a smartphone, and when pointed towards the patient, the app analyses their lip movements to decipher what they are trying to say. SRAVI is being trialled in Intensive Care units within the NHS. $589.6K / Seed / Apr 08, 2019
SupaPass is an all-in-one website and app creation platform for any business to launch its own website and apps. SupaPass allows anyone to create beautiful and powerful, payment-ready, all-in-one content website and mobile apps instantly without any technical knowledge.With millions of individuals and businesses globally needing a launch-ready,affordable content driven website and app, SupaPass is an innovative white-label platform that allows clients to retain 100% of sales and full ownership of customer data at the touch of a button. It offers more cost-effective and intuitive designs to make content such as podcasts, video, audio and streaming channels more manageable, it is over 10 times faster and cheaper than custom-built solutions.With SupaPass’s technology clients are able to keep their own brand front and control how they interact with their customers. With a content layout similar to Netflix and Prime, SupaPass gives clients the tools they need to have everything in one place to grow their business online. It services a wide range of sectors and verticals including Podcasting, Fitness, and Wellbeing, TV and Film, Archives, Membership Organisations, Music, Sport, Charities, Conferences, and Consultancies.SupaPass was founded in 2011. $507.6K / Seed / Dec 30, 2018
Lightpoint Medical is an early-stage medical device company founded in 2012. The company is developing a breakthrough intraoperative imaging technology called Cerenkov Luminescence Imaging (CLI). CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the likelihood of cancer recurrence and the need for reoperation. $6.4M / Series B / Dec 06, 2018
Pertinax Pharma Ltd. is a patent-protected, sustained release technology for chlorhexidine, a common antiseptic. Pertinax have developed an innovative range of controlled release antimicrobial materials with applications across many industries and sectors. $1.1M / Venture - Series Unknown / Oct 11, 2018
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection $1.7M / Venture - Series Unknown / Sep 14, 2018
infloAi is a London-based software company building proprietary AI technology to make content creation simple, fast and affordable for any business.Currently, content teams are forced to stitch together multiple solutions, use expensive agencies or they simply cannot produce the level of engaging content required - turning their back on valuablerevenue. infloAi changes that: our technology helps streamline the process through clever automation - making it simple to produce content that will increase engagement and revenues.We’re now looking to grow our core team before raising Series A in Q4 2019. $848.6K / Seed / Sep 04, 2018
Gelmetix develops multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery for conditions like Chronic Lower Back pain and Osteoarthritis. Their lead product is a hydrogel for nucleus pulposus augmentation to relieve pain in patients suffering from Chronic Low Back Pain. Gelmetix is a diversified therapeuticbiomaterials company incorporated in the UK. It has offices in London, Paris, and Manchester. $1.6M / Series B / Sep 01, 2018
Naked Energy has developed an innovative hybrid solar technology generating combined heat and power.The versatile, modular design of Virtu® places crystalline photovoltaic cells in an evacuated solar thermal collector. For any given area more of the sun’s energy is converted into heat and electricity (80% of the 1000W/m2 available) thanksto the patented heat transfer mechanism.Thermal and electrical outputs are optimized irrespective of geographic or climatic conditions. With the isothermally cooled PV cells protected from the environment, Virtu® is especially suited to harsh high-insolation markets.Naked Energy is in the final stages of preparing for commercial launch to address global applications for domestic, commercial and industrial customers. Virtu® is both disruptive and scalable. $1.5M / Venture - Series Unknown / Aug 23, 2018
Mayku provides a platform for creators to access machines, materials, and services in order to create their own products. FormBox, Mayku's product, is a desktop-sized vacuum former that allows users to easily create a mold or model of their choice at a low cost. Mayku's other product, the Multiplier, is a machine that uses pressureforming to enable rapid production scaling. Mayku enables the manufacture of products locally, quickly, and affordably by providing creators with the hardware, raw materials, and software required to produce a wide range of items. It accelerates the global shift to local manufacturing. $598K / Seed / May 31, 2018
Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than 3 minutes with no prior sample preparation the Arcis DNA Prep range of products allow users to quickly andconveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment and requires as little as 30µl of blood as a starting material. Arcis DNA products can be used on many different samples containing DNA including whole blood, plasma, urine, buccal swabs, and hair follicles . $1.6M / Equity Crowdfunding / Apr 16, 2018
See all 34 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Mobile
Oil and Gas
Film
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Sports
Education
Biotechnology
Legal
Automotive
eSports
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Beauty
Fashion
Web3
Infrastructure
Recruiting
Social
Celebrity
Food and Beverage
Cannabis
LGBT
Life Science
Climate
Real Estate
Sporting Goods
Publishing
Music
Art
Wine and Spirits
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Mobile Apps
Android
Impact
Proptech
Hardware
Enterprise
Transportation
Biotech
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Poland
Oman
Puerto Rico
Guernsey
Colombia
Cameroon
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Honduras
Israel
Lithuania
Cambodia
Iceland
Liechtenstein
Mongolia
Lebanon
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Fund Twenty8 invest in?

Fund Twenty8 invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Venture - Series Unknown stage. Most of the 34 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Fund Twenty8 invest in?

Fund Twenty8 typically joins rounds of $508k–$1.9M at Seed, $2.3M–$3.4M at Series A and $414k–$3.1M at Venture - Series Unknown. These are whole funding-round sizes, not Fund Twenty8's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Fund Twenty8 took part in.

How do I contact Fund Twenty8?

Public channels for Fund Twenty8 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Fund Twenty8?

The team at Fund Twenty8 includes Goncalo de Vasconcelos (CEO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Fund Twenty8 Fund Twenty8 Find emails